Literature DB >> 12153921

Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ.

Lise L Kjaergard1, Bodil Als-Nielsen.   

Abstract

OBJECTIVE: To assess the association between competing interests and authors' conclusions in randomised clinical trials.
DESIGN: Epidemiological study of randomised clinical trials published in the BMJ from January 1997 to June 2001. Financial competing interests were defined as funding by for profit organisations and other competing interests as personal, academic, or political. STUDIES: 159 trials from 12 medical specialties. MAIN OUTCOME MEASURES: Authors' conclusions defined as interpretation of extent to which overall results favoured experimental intervention. Conclusions appraised on 6 point scale; higher scores favour experimental intervention.
RESULTS: Authors' conclusions were significantly more positive towards the experimental intervention in trials funded by for profit organisations alone compared with trials without competing interests (mean difference 0.48 (SE 0.13), P=0.014), trials funded by both for profit and non-profit organisations (0.30 (SE 0.10), P=0.003), and trials with other competing interests (0.45 (SE 0.13), P=0.006). Other competing interests and funding from both for profit and non-profit organisations were not significantly associated with authors' conclusions. The association between financial competing interests and authors' conclusions was not explained by methodological quality, statistical power, type of experimental intervention (pharmacological or non-pharmacological), type of control intervention (for example, placebo or active drug), or medical specialty.
CONCLUSIONS: Authors' conclusions in randomised clinical trials significantly favoured experimental interventions if financial competing interests were declared. Other competing interests were not significantly associated with authors' conclusions.

Keywords:  Biomedical and Behavioral Research; Empirical Approach

Mesh:

Year:  2002        PMID: 12153921      PMCID: PMC117638          DOI: 10.1136/bmj.325.7358.249

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  13 in total

1.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.

Authors:  D Moher; K F Schulz; D G Altman
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

2.  Beyond conflict of interest. Sponsored drug trials show more-favourable outcomes.

Authors:  K Wahlbeck; C Adams
Journal:  BMJ       Date:  1999-02-13

3.  Are randomised controlled trials in the BMJ different?

Authors:  M Egger; C Bartlett; P Jüni
Journal:  BMJ       Date:  2001-11-24

4.  Sponsorship, authorship, and accountability.

Authors:  F Davidoff; C D DeAngelis; J M Drazen; J Hoey; L Højgaard; R Horton; S Kotzin; M Nylenna; A J Overbeke; H C Sox; H C Sox; M B Van Der Weyden; M S Wilkes
Journal:  Ann Intern Med       Date:  2001-09-18       Impact factor: 25.391

5.  The uncertainty principle and industry-sponsored research.

Authors:  B Djulbegovic; M Lacevic; A Cantor; K K Fields; C L Bennett; J R Adams; N M Kuderer; G H Lyman
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

6.  Funding clinical research.

Authors:  P Dieppe; J Chard; D Tallon; M Egger
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

7.  Beyond conflict of interest. Transparency is the key.

Authors:  R Smith
Journal:  BMJ       Date:  1998-08-01

8.  Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

Authors:  D Moher; B Pham; A Jones; D J Cook; A R Jadad; M Moher; P Tugwell; T P Klassen
Journal:  Lancet       Date:  1998-08-22       Impact factor: 79.321

9.  Comparing several groups using analysis of variance.

Authors:  D G Altman; J M Bland
Journal:  BMJ       Date:  1996-06-08

10.  Improving the quality of reporting of randomized controlled trials. The CONSORT statement.

Authors:  C Begg; M Cho; S Eastwood; R Horton; D Moher; I Olkin; R Pitkin; D Rennie; K F Schulz; D Simel; D F Stroup
Journal:  JAMA       Date:  1996-08-28       Impact factor: 56.272

View more
  95 in total

1.  Of mugs, meals and more: the intricate relations between physicians and the medical industry.

Authors:  Stephan Sahm
Journal:  Med Health Care Philos       Date:  2013-05

2.  Randomized clinical trials: what gets published, and when?

Authors:  Laurence Hirsch
Journal:  CMAJ       Date:  2004-02-17       Impact factor: 8.262

3.  Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials.

Authors:  Mohit Bhandari; Jason W Busse; Dianne Jackowski; Victor M Montori; Holger Schünemann; Sheila Sprague; Derek Mears; Emil H Schemitsch; Dianne Heels-Ansdell; P J Devereaux
Journal:  CMAJ       Date:  2004-02-17       Impact factor: 8.262

4.  Medical reversal: why we must raise the bar before adopting new technologies.

Authors:  Vinay Prasad; Adam Cifu
Journal:  Yale J Biol Med       Date:  2011-12

5.  Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals.

Authors:  F Alfonso; A Timmis; F J Pinto; G Ambrosio; H Ector; P Kulakowski; P Vardas
Journal:  Neth Heart J       Date:  2012-06       Impact factor: 2.380

Review 6.  Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review.

Authors:  Claudia Steurer-Stey; Leonie Lagler; Daniel A Straub; Johann Steurer; Lucas M Bachmann
Journal:  Eur J Pediatr       Date:  2006-11-18       Impact factor: 3.183

7.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Authors:  David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman
Journal:  BMJ       Date:  2010-03-23

8.  The availability of references and the sponsorship of original research cited in pharmaceutical advertisements.

Authors:  Richelle J Cooper; David L Schriger
Journal:  CMAJ       Date:  2005-02-15       Impact factor: 8.262

9.  The limits of disclosure: what research subjects want to know about investigator financial interests.

Authors:  Christine Grady; Elizabeth Horstmann; Jeffrey S Sussman; Sara Chandros Hull
Journal:  J Law Med Ethics       Date:  2006       Impact factor: 1.718

10.  Evolution of the randomized controlled trial in oncology over three decades.

Authors:  Christopher M Booth; David W Cescon; Lisa Wang; Ian F Tannock; Monika K Krzyzanowska
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.